NY Post : FTC review to delay Cabela’s-Bass Pro merger

The merger of Bass Pro Shops and Cabela’s has hit a speed bump.

The Federal Trade Commission has asked Bass Pro Shops for more information on its $5.5 billion merger with Cabela’s, a move that is likely to hold up the deal for several months, The Post has learned.

Regulators this week needed to let the leading outdoors retailers know if they were prepared to clear the October merger after their first review.

They told the parties they are still hunting for more details about how the deal will impact competition, commonly referred to as a second request, two sources close to the situation said.

“The regulatory process will now take more than another month or two,” a source said.

Bass Pro has agreed to pay Cabela’s $65.50 a share. Cabela’s shares have risen from $60.65 on Nov. 14 to close Monday at $62.47 on the expectation the deal could close this week.

Cabela’s, though, on Oct. 26 set less optimistic expectations saying on an analyst call that the deal was expected to be completed in the first half of 2017.

In a confidential Bass lender presentation Bass said 45 percent of Bass Pro customers also shop at Cabela’s.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: SCVL -13.4%, SOL -7.6%, MTL -5%, FRO -1.7%, MNK -0.5%

Select metals/mining stocks trading lower:
  • HMY -5.3%, SBGL -4.2%, GFI -3.6%, CLF -3.6%, VALE -3.3%, FCX -3%, AU -2.4%, GDX -2%, AG -2%, PAAS -2%, HL-1.8%, ABX -1.8%
  • RIO -1.6%, IAG -1.6%, NEM -1.6%, BHP -1.4%, BBL -1.3%, MT -0.9%, GLD -0.9%
Select oil/gas related names showing early weakness: WLL -2.6%, OAS -2.4%, SDRL -2%, RIG -1.2%, HAL -1.1%,RDS.A -0.8%, CHK -0.8%

Other news:
  • NVLS -54.7% ( Phase 2 trial evaluating efficacy and safety of two doses of cavosonstat failed to demonstrate benefit in absolute change in percent predicted FEV1 or in sweat chloride reduction at 12 weeks)
  • FOLD -26.7% ( announces U.S. regulatory pathway for Migalastat for Fabry Disease)
  • GLBS -7.6% (after stock doubled on Monday)
  • BOJA -6.3% ( announces a 6 mln share underwritten public offering of common stock by selling shareholders )
  • TCBI -3.8% (prices 3.0 mln shares of common stock for gross proceeds of $210.0 mln )
  • COTV -3.5% ( commences 10 mln common stock offering by selling stockholders)
  • BIP -3.5% (light volume; Brookfield Infrastructure announces $750 million equity offering)
  • FDUS -3.4% (commences registered public offering of 2.5 mln shares of common stock through an underwritten public offering)
  • SITE -3.1% (ticking lower; commences 8 mln common stock offering by selling stockholders Clayton, Dubilier & Rice, LLC, and Deere & Company)
Analyst comments:
  • AKS -3.5% (downgraded to Neutral from Outperform at Macquarie)
  • X -3% (downgraded to Hold from Buy at Argus)
  • RS -1.3% (downgraded to Neutral from Outperform at Macquarie)
  • MCD -0.8% (removed from US Focus List at Credit Suisse)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: THO +8.6%, TIF +5.1%, BERY +4.6%, UNH +3.2%, ZTO +2.6%, BNS +1.3%

M&A news: RMAX +1.4% (light volume; acquires the Master Franchise for the Georgia, Kentucky/Tennessee, and Southern Ohio Regions; terms not disclosed)

Select financial related names showing strength: DB +2.8%, PUK +1.6%, ING +1.3%, CS +0.8%, LYG +0.7%

Other news:
  • CYTR +42.9% (announces 'positive' updated results from its pivotal Phase 3 clinical trial evaluating aldoxorubicin)
  • CBMX +29.6% (announces that its pre-implantation genetic screening by next generation sequencing test has received conditional approval from the New York State Department of Health)
  • VBLT +22% (announces top-line results from its exploratory Phase 2 study of VB-111g)
  • MNTA +12.2% (Phase 3 clinical study of M923 in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint)
  • OCUL +11.8% (to present at Piper Jaffray Healthcare Conference tomorrow)
  • KNDI +6.9% (received a second subsidy payment of RMB 100 million)
  • P +5% (Pete Najarian in the 'Final Trade' segment of CNBC's Fast Money program pointed out 'huge call buying' that occured late in yesterday's session)
  • TIVO +3.9% (TiVo and Netflix enter into product and intellectual property agreements)
  • PZRX +3.5% (following 150% move higher on Monday)
  • ARIA +3.3% (FDA has granted Iclusig full approval)
  • SAN +1.6% (receives ECB decision for 2017 capital requirements; must maintain CET1 ratio of 7.75%)
  • BT +1.1% (appoints Chairman of Openreach; provides response to Ofcom statement)
Analyst comments:
  • BCS +2.8% (initiated with an Outperform at Credit Suisse)
  • ONVO +2.2% (initiated with a Buy at Evercore ISI)
  • FIT +1.5% (Longbow out positive following FIT's strong showing this holiday weekend)
  • PFE +0.9% (upgraded to Overweight from Equal Weight at Barclays)

FT : FCA lays out Logica insider trading case

A former business analyst at Logica allegedly passed inside information about its £1.7bn takeover by CGI Group to his London neighbour and to his brother-in-law, a court has heard.
The UK’s Financial Conduct Authority has charged Manjeet Singh Mohal with two counts of passing on inside information on 28th May 2012, three days before the Reading-based technology services company disclosed an approved takeover by CGI. That announcement prompted the FTSE 250 company’s share price soar from 65.7 pence to 110 pence.

‎Reshim Birk, Mr Mohal’s neighbour in the London suburb of Southall, bought shares and options in Logica after ‎a tip-off from Mr Mohal, the FCA alleges. Surinder Pal Singh Sappal, his brother-in-law through his sister, also bought shares, the watchdog says. Mr Birk and Mr Sappal face one count each of insider trading, according to the indictment.

Mr Mohal, who had worked at the company for a decade as a business analyst, was not included on Logica’s formal list of insiders on the takeover, but in 2004 he signed an official company code of conduct around inside information “akin to the Official Secrets Act,” Andrew Marshall for the FCA said on Tuesday.

“The prosecution ‎case is that when you look at the evidence, there’s clear evidence that he must have obtained inside information and that he then disclosed it to Reshim Birk and Mr Soppal,” Mr Marshall told the jury at the Old Bailey. “We can’t say precisely how he got that information. We don’t have to prove it either.”

Mr Mohal sat next to Ryan Willmott in Logica’s office. Mr Willmott was on the insider list for the takeover and was gathering information about the deal, the jury heard. Mr Mohal was assisting Mr Willmott in the weeks running up to the takeover. The group finance director has given evidence that she was “surprised” Mr Mohal was not considered an insider, the jury heard.

Mr Mohal called his neighbour, Mr Birk, in the early evening of 28th May as the Logica board was meeting to discuss the deal announcement, the jury heard. The next morning, Mr Birk called his broker at Investec and bought £20,000 of Logica shares and, unusually for his portfolio, £5,000 worth of options, saying he had a “hunch” about a possible takeover — prompting a warning from the broker over illegal trading. A suspicious transaction report was filed by Investec the next day.

The defendants deny the charges and now face a four-week trial.

Insider trading carries a maximum sentence of seven years in prison — although the longest sentence meted out in the UK to date has been four-and-a-half years in another FCA case earlier this year.

Witnesses in the trial will include Charles Wilkinson, who was head of corporate broking at Deutsche Bank at the time, advising Logica on the takeover. ‎Logica officials will also appear as witnesses.

The trial comes after probe by the FCA dubbed Operation Holt.

The besuited defendants sat silently in the dock as Mr Marshall outlined the prosecution case to the jury.

The trial continues.